Biologics targeting upstream alarmins (e.g., IL-33/TSLP) and downstream cytokines (e.g., IL-1β, IL-6) aim to disrupt inflammatory redundancy; cell-based and regenerative approaches represent long-term precision strategies for emphysema. The gene discussed is IL33; the disease is pulmonary emphysema.